MK
Michael Khodadoust
Research areas: Medicine · Pathology and Forensic Medicine · Lymphoma Diagnosis and Treatment · Cutaneous lymphoproliferative disorders research · Cancer Genomics and Diagnostics
0000-0001-9061-7351
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (187)
- A practical approach to risk stratification of incidental T-cell clonality Save
- Rosai-Dorfman Disease: A 30-Year Institutional Study of Clinical Features, Treatment Patterns, and Outcomes Save
- Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas. Save
- Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia. Save
- Updated Clinical Data From the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients With Relapsed/Refractory Cytotoxic T/NK Cell Lymphomas Save
- Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders. Save
- Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-cell Lymphoproliferative Disorders Save
- "Leukemic pernio": perniosis-like presentations of chronic lymphocytic leukemia. Save
- Data from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors Save
- Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors Save
- Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors Save
- Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine. Save
- Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas Save
- Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) Save
- T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas Save
- Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas Save
- A Phase 2 Study of Low-Dose Total Skin Electron Beam Therapy (LD-TSEBT) Combined with Mogamulizumab (TSE-Moga) in patients with Mycosis Fungoides (MF) and Sezary Syndrome (SS) Save
- JAK2 fusions in mycosis fungoides and Sezary Syndrome and treatment with ruxolitinib Save
- Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma Save
- Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling. Save